Rates of Progression in Patients with Alzheimer’s Disease Depending on Apolipoprotein E Genotype and Concomitant Medications.
Background: The apolipoprotein E (APOE) ε4 allele is associated with higher cholesterol levels, and an increased risk of developing Alzheimer’s disease (AD) and amyloid-related imaging abnormalities after initiation of amyloid-modifying therapies. A worse cognitive response to cholinesterase inhibitor (ChEI) treatment and longitudinal outcome in APOE ε4-carriers has been observed. Based on these c
